These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 17235304)

  • 21. Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy.
    Ko YT; Falcao C; Torchilin VP
    Mol Pharm; 2009; 6(3):971-7. PubMed ID: 19317442
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
    Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
    Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression.
    Chi KC; Wallis AE; Lee CH; De Menezes DL; Sartor J; Dragowska WH; Mayer LD
    Breast Cancer Res Treat; 2000 Oct; 63(3):199-212. PubMed ID: 11110054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen).
    Raffo A; Lai JC; Stein CA; Miller P; Scaringe S; Khvorova A; Benimetskaya L
    Clin Cancer Res; 2004 May; 10(9):3195-206. PubMed ID: 15131061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE
    J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Delivery of G3139 using releasable PEG-linkers: impact on pharmacokinetic profile and anti-tumor efficacy.
    Zhao H; Peng P; Longley C; Zhang Y; Borowski V; Mehlig M; Reddy P; Xia J; Borchard G; Lipman J; Benimetskaya L; Stein CA
    J Control Release; 2007 Jun; 119(2):143-52. PubMed ID: 17397960
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of Bcl-2 antisense oligonucleotide (G3139) combined with doxorubicin in SCID mice bearing human breast cancer solid tumor xenografts.
    Lopes de Menezes DE; Mayer LD
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):57-68. PubMed ID: 11855753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transferrin receptor targeted lipopolyplexes for delivery of antisense oligonucleotide g3139 in a murine k562 xenograft model.
    Zhang X; Koh CG; Yu B; Liu S; Piao L; Marcucci G; Lee RJ; Lee LJ
    Pharm Res; 2009 Jun; 26(6):1516-24. PubMed ID: 19291371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
    van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM
    Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antitumor effect of bcl-2 antisense phosphorothioate oligodeoxynucleotides on human renal-cell carcinoma cells in vitro and in mice.
    Uchida T; Gao JP; Wang C; Satoh T; Itoh I; Muramoto M; Hyodo T; Irie A; Akahoshi T; Jiang SX; Kameya T; Baba S
    Mol Urol; 2001; 5(2):71-8. PubMed ID: 11690551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structural optimization and additional targets identification of antisense oligonucleotide G3139 encapsulated in a neutral cytidinyl-lipid combined with a cationic lipid in vitro and in vivo.
    Ma Y; Zhao W; Li Y; Pan Y; Wang S; Zhu Y; Kong L; Guan Z; Wang J; Zhang L; Yang Z
    Biomaterials; 2019 Mar; 197():182-193. PubMed ID: 30660994
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Polyethylenimine-Containing and Transferrin-Conjugated Lipid Nanoparticle System for Antisense Oligonucleotide Delivery to AML.
    Yuan Y; Zhang L; Cao H; Yang Y; Zheng Y; Yang XJ
    Biomed Res Int; 2016; 2016():1287128. PubMed ID: 27034925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bcl-2 antisense oligonucleotides chemosensitize human gastric cancer in a SCID mouse xenotransplantation model.
    Wacheck V; Heere-Ress E; Halaschek-Wiener J; Lucas T; Meyer H; Eichler HG; Jansen B
    J Mol Med (Berl); 2001 Oct; 79(10):587-93. PubMed ID: 11692156
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.
    Ramanarayanan J; Hernandez-Ilizaliturri FJ; Chanan-Khan A; Czuczman MS
    Br J Haematol; 2004 Dec; 127(5):519-30. PubMed ID: 15566355
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
    Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
    Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined blockade of protein kinase A and bcl-2 by antisense strategy induces apoptosis and inhibits tumor growth and angiogenesis.
    Tortora G; Caputo R; Damiano V; Bianco R; Fontanini G; Cuccato S; De Placido S; Bianco AR; Ciardiello F
    Clin Cancer Res; 2001 Aug; 7(8):2537-44. PubMed ID: 11489837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice.
    Schlagbauer-Wadl H; Klosner G; Heere-Ress E; Waltering S; Moll I; Wolff K; Pehamberger H; Jansen B
    J Invest Dermatol; 2000 Apr; 114(4):725-30. PubMed ID: 10733680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
    Mohammad R; Abubakr Y; Dan M; Aboukameel A; Chow C; Mohamed A; Hamdy N; Al-Katib A
    Clin Cancer Res; 2002 Apr; 8(4):1277-83. PubMed ID: 11948143
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphorothioate oligonucleotides reduce mitochondrial outer membrane permeability to ADP.
    Tan W; Lai JC; Miller P; Stein CA; Colombini M
    Am J Physiol Cell Physiol; 2007 Apr; 292(4):C1388-97. PubMed ID: 17135295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.